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Background & aims: The Swiss supplemental parenteral nutrition (SPN) study demonstrated that opti-
mised energy provision combining enteral nutrition (EN) and SPN reduces nosocomial infections in
critically ill adults who fail to achieve targeted energy delivery with EN alone. To assess the economic
impact of this strategy, we performed a cost-effectiveness analysis using data from the SPN study.
Methods: Multivariable regression analyses were performed to characterise the relationships between
SPN, cumulative energy deﬁcit, nosocomial infection, and resource consumption. The results were used
as inputs for a deterministic simulation model evaluating the cost-effectiveness of SPN administered on
days 4e8 in patients who fail to achieve 60% of targeted energy delivery with EN by day 3. Cost data
were derived primarily from Swiss diagnosis-related case costs and ofﬁcial labour statistics.
Results: Provisionof SPNondays4e8was associatedwith ameandecreaseof 2320± 338 kcal in cumulative
energy deﬁcit compared with EN alone (p < 0.001). Logistic regression analysis showed that each 1000 kcal
decrease in cumulative energydeﬁcitwas associatedwith a 10% reduction in the risk of nosocomial infection
(odds ratio 0.90; 95% conﬁdence interval 0.83e0.99; p < 0.05). The incremental cost per avoided infection
was 63,048 CHF, indicating that the reduction in infection was achieved at a lower cost.
Conclusion: Optimisation of energy provision using SPN is a cost-saving strategy in critically ill adults for
whom EN is insufﬁcient to meet energy requirements.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adequate nutrition support is vitally important in the man-
agement of patients in the intensive care unit (ICU) [1e3]. Due to
the persistent metabolic demands and the difﬁculty of initiating
feeding in ICU patients, energy deﬁcits accumulate rapidly during
the ﬁrst week following admission to the ICU [4], leading to an
increased risk of infection, prolonged duration on mechanical
ventilation, longer stay in the ICU, and increasedmortality [5e9]. To
prevent such complications, clinical practice guidelines recom-
mend early initiation of enteral nutrition (EN) in haemodynami-
cally stable critically ill patients who are unable to maintain
volitional intake [1e4]. However, EN alone is often insufﬁcient to
meet energy and protein requirements [10e15]. As a result, ai).
r Ltd. This is an open access article usigniﬁcant proportion of critically ill patients fail to achieve
adequate nutritional intake [12].
Supplemental parenteral nutrition (SPN) has been shown to
improve the cumulative energy balance and reduce infectious
morbidity in ICU patients who fail to achieve energy and protein
goals with EN alone [16]. Nonetheless, parenteral nutrition (PN) is
often withheld in practice due to cost and perceived risks [17e21].
In the Swiss SPN study, we tested the hypothesis that individually
optimised energy provision using EN plus SPN would improve
clinical outcomes in critically ill patients who fail to achieve 60%
of energy goals with EN alone by day 3. The ﬁndings showed that
supplemental administration of PN on days 4e8 resulted in a 35%
reduction in the adjusted risk of nosocomial infection compared
with continued administration of EN alone (hazard ratio 0.65; 95%
conﬁdence interval [CI] 0.43e0.97; p ¼ 0.03) [16]. To assess the
economic impact of this strategy, we performed a cost-
effectiveness analysis using modelled outcomes derived from the
Swiss SPN study.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The primary objective of the study was to evaluate the cost-
effectiveness of SPN in critically ill adult ICU patients who fail to
achieve 60% of calculated energy targets with EN alone. A deter-
ministic model-based analysis integrated clinical data from the SPN
trial with cost data derived from other sources to simulate clinical
outcomes and resource utilisation in the target population. Data
from the SPN study were analysed using multivariable regression
models to sequentially characterise the relationships between
nutritional intervention, cumulative energy deﬁcit, and nosocomial
infection. Linear multiple regression analysis was then used to es-
timate the effect of nosocomial infection on resource consumption
parameters such as antibiotic use, duration of mechanical ventila-
tion, and length of stay in the ICU and hospital. Finally, effect size
estimates from the multivariable analyses and cost estimates
derived primarily from Swiss diagnosis-related case costs were
used as model inputs for a pharmacoeconomic analysis to evaluate
the cost-effectiveness of SPN.
2.1. Source datadclinical outcomes
The source population for the analysis of clinical outcomes
included all patients enrolled in the Swiss SPN Study (N ¼ 305;
ClinicalTrials.gov registration number, NCT00802503) [16]. Study
design and enrolment criteria have been previously described [16].
Brieﬂy, eligible patients were critically ill adults with a functional
gastrointestinal tract who failed to achieve60% of targeted energy
delivery with EN by day 3 following ICU admission. Patients were
randomised to receive continued EN alone or EN plus SPN on days
4e8 with the aim of delivering 100 percent of the energy expen-
diture measured by indirect calorimetry. There was no catch-up
feeding of the previous deﬁcit. The primary study endpoint was
the occurrence of nosocomial infections between days 9 and 28,
deﬁned according to the Centers for Disease Control and Prevention
[22].
2.2. Source datadcost analysis
Unit costs for medical resources were derived primarily from
the Swiss Federal Statistical Ofﬁce 2013 diagnosis-related case costs
for a sample population of 7614 mechanically ventilated adult ICU
patients with a Simpliﬁed Acute Physiology II (SAPS II) score >30
and an ICU stay 3 days. The cost of SPN was calculated as the
acquisition cost of a representative PN product (StructoKabiven®,
Fresenius Kabi GmbH; 1 bag per day administered for 4 days) plus
the cost of medical staff to prescribe and administer PN. The latter
was estimated based on gross wages for medical and nursing staff
obtained from the Swiss Federal Statistical Ofﬁce and the mean PN
administration times reported in a previous time-and-motion
study [23]. Daily costs for standard doses of antimicrobial therapy
for nosocomial infectionwere obtained via interviews with experts
from two Swiss university hospitals (interviews conducted by
Polynomics AG, Olten, Switzerland, August 2015).
2.3. Statistical analysisdclinical outcomes and resource utilisation
Linear multivariable regression analysis was used to character-
ise the relationship between potential explanatory variables and
cumulative energy deﬁcit during days 1e8 in the SPN trial. Logistic
multivariable analysis was used to examine the relationship be-
tween potential explanatory variables and nosocomial infection
from day 9 to day 28. Additionally, the effect of nosocomial infec-
tion on medical resource consumption (antibiotic days, hours on
mechanical ventilation, length of stay in the ICU, and length of stayin the ward) was estimated using linear multivariable regression
analysis. Potential explanatory variables included age, gender,
height, weight, body mass index (BMI), diagnosis, institution, Acute
Physiology and Chronic Health Evaluation II (APACHE II) score,
baseline infection status, duration of prophylactic antibiotic ther-
apy, cumulative energy deﬁcit during days 1e8, mean percentage of
energy target achievement on days 1e8, and mean energy delivery
on days 1e8. Independent variables were selected for the initial
models based on the strength of associations in unadjusted uni-
variable analyses. Multi-collinearity was evaluated using the vari-
ance inﬂation factor (VIF). Among coupled variables with a VIF
>2.50, the variable with the weaker association was eliminated
from the model. Parameter estimates for the linear regression an-
alyses were evaluated using the Student t-test. The fully speciﬁed
multivariable model was evaluated using Fisher's exact test. The
logistic regression model was evaluated using the z-test. All ana-
lyses were performed using R statistical software, version 3.1.2 (R
Foundation, Vienna, Austria).
Analyses evaluating resource consumption parameters as the
response variable were based on the full dataset from the intent-to-
treat population in the Swiss SPN study (N ¼ 305). Analyses eval-
uating cumulative energy deﬁcit and nosocomial infection as the
response variable were based on the per protocol population
(N ¼ 275) due to missing data for cumulative energy deﬁcit
(N ¼ 30).
2.4. Cost-effectiveness analysis
The cost-effectiveness analysis was conducted from the
perspective of Swiss hospitals. Effect size estimates derived from
the Swiss SPN study were used as model inputs for a pharmacoe-
conomic model evaluating the cost-effectiveness of SPN compared
with continued EN in critically ill patients who fail to achieve tar-
geted energy delivery with EN. Discrete event simulation was used
to model patient outcomes following ICU admission in two cohorts
(Fig. 1) [24]. The time horizon of the model corresponds with the
observation period in the clinical trial. The initial step in the model
was the decision to either continue EN therapy alone or add SPN.
Patients receiving EN alone were assigned a cumulative energy
deﬁcit based on the observed cumulative energy deﬁcit for days
1e8 in the corresponding treatment group in the SPN trial. For
those receiving SPN, the cumulative energy deﬁcit was determined
by applying the estimated nutritional advantage attributed to SPN
in the multivariable analysis to the observed cumulative energy
deﬁcit in the EN group. The occurrence of infection in patients
receiving EN was determined based on the observed probability of
nosocomial infection between days 9 and 28 in the EN group during
the SPN study. In patients receiving SPN, the occurrence of infection
was based on the adjusted odds ratio (OR) for nosocomial infection
in the logistic regression analysis. For patients without infection,
values for resource utilisation parameters were based on the
observed mean values for non-infected patients in the SPN trial; for
patients with infection, adjusted estimates from the multivariable
analyses were used.
The primary outcome of the pharmacoeconomic analysis was
the incremental cost per infection avoided, reported in Swiss francs
(CHF). All direct hospital costs from the time of admission until
discharge were included in the model and assigned to one of the
following categories: ICU stay, ward stay, mechanical ventilation,
antimicrobial therapy, and SPN administration. Because the time
horizon was limited to the hospital stay, future costs and outcomes
were not discounted.
A probabilistic sensitivity analysis was conducted to assess the
effect of uncertainty surrounding parameter estimates. Addition-
ally, a one-way deterministic sensitivity analysis was performed to
Fig. 1. Schematic representation of the pharmacoeconomic model. Abbreviations: EN, enteral nutrition; ICU, intensive care unit; LOS, length of stay; SPN, supplemental parenteral
nutrition.
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terventions to variations in estimated values for each model
parameter.3. Results
3.1. Clinical outcomes
Model-derived estimates for clinical outcomes and resource
utilisation parameters are presented in Table 1 (see Data
Supplement for the fully speciﬁed models). Multivariable analysis
of data from the SPN study showed a statistically signiﬁcant asso-
ciation between the provision of SPN on days 4e8 and cumulative
energy deﬁcit during days 1e8. A statistically signiﬁcant association
was also observed between cumulative energy deﬁcit during days
1e8 and the risk of nosocomial infection from day 9 to day 28. After
adjustment for covariates, provision of SPN on days 4e8 was
associated with a mean (SD) difference of 2320 kcal (338) in cu-
mulative energy deﬁcit compared with EN alone (p < 0.001). Lo-
gistic regression analysis showed that each 1000 kcal decrease in
cumulative energy deﬁcit was associated with a 10% relative
reduction in the risk of nosocomial infection (OR 0.90; 95% CI
0.83e0.99; p < 0.05) between day 9 and day 28. Based on theTable 1
Model-derived estimates for clinical outcomes and resource utilisation parameters.a
Effect of SPN on cumulative energy deﬁcitb
EN
Mean cumulative energy deﬁcit, kcal 6702 (296)c
Effect of cumulative energy deﬁcit on risk of infectiond
EN
Nosocomial infection 38.0%c
Effect of infection on mean resource utilisationf
New infection
Antibiotic use, days 11.1 (1.0)
Mechanical ventilation, hours 94.5 (13.0)
ICU length of stay, days 18.1 (1.4)
Ward length of stay, days 28.3 (3.6)
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CI, conﬁdence
standard error; SPN, supplemental parenteral nutrition.
a Based on data from the Swiss SPN study [16].
b Linear regression analysis, adjusted for sex, institution, and patient type (medical vs
c Observed result, Swiss SPN study.
d Logistic regression analysis, adjusted for age, APACHE II score, and cumulative energ
e Derived from the adjusted risk of nosocomial infection per 1000 kcal decrease in energ
energy deﬁcit between treatment groups.
f Linear regression analysis, adjusted for relevant baseline covariates (see appendix inadjusted mean difference in cumulative energy deﬁcit between the
two treatment groups, an adjusted OR of 0.80 (95% CI 0.63e0.98)
was used to determine the incidence of infection in the SPN cohort
in the pharmacoeconomic model.
Linear multivariable regression analyses evaluating predictors
of hospital resource utilisation showed statistically signiﬁcant as-
sociations between nosocomial infection and antibiotic use (mean
increase, 8.3 days [standard error, 0.7], p < 0.001), duration of
mechanical ventilation (mean increase, 64.8 h [11.6], p < 0.001),
and length of stay in both the ICU (mean increase, 7.7 days [1.2],
p < 0.001) and the ward (mean increase, 11.9 days [3.1], p < 0.001;
Table 1).3.2. Cost-effectiveness evaluation
Unit costs for the resource utilisation parameters in the phar-
macoeconomic model are summarised in Table 2. Deterministic
simulation analysis using the mean values for clinical and resource
utilisation parameters yielded total hospitalisation costs of 112,338
CHF and 108,999 CHF per patient in the EN and SPN groups,
respectively, resulting in an estimated net cost reduction of 3339
CHF per patient with the SPN strategy (Table 3). Based on the 5.3%
absolute reduction in nosocomial infections in patients receivingSPN Mean difference p-value
4383 (363) 2320 (338) <0.001
SPN Odds ratio (95% CI) p-value
32.7% 0.80 (0.63e0.98)e <0.05
No new infectionc Mean difference p-value
2.75 (0.4) 8.34 (0.7) <0.001
29.7 (5.1) 64.8 (11.6) <0.001
10.4 (0.6) 7.72 (1.2) <0.001
16.4 (1.4) 11.9 (3.1) <0.001
interval; EN, enteral nutrition; ICU, intensive care unit; SD, standard deviation; SE,
. surgical); data are presented as mean (SD).
y balance for days 1e8.
y deﬁcit (OR 0.90; 95% CI 0.83e0.99) and the adjustedmean difference in cumulative
data supplement); data are presented as mean (SE).
Table 2
Unit costs for medical resource utilisation parameters.a
Mean unit cost (CHF) SD or 95% CI
ICU stay, dayb 5055 SD, 2167
Ward stay, dayb 1900 SD, 1182
Mechanical ventilation, hourb 85.4 95% CI, 77e94
Antimicrobial therapy, dayc 65.0 95% CI, 60e70
Interventiond 247 SD, 49
Abbreviations: CI, conﬁdence interval; ICU, intensive care unit; SD, standard
deviation.
a Conversion: 1 CHF ¼ V0.92 ¼ US$1.02 (based on published exchange rates on 1
November 2016).
b Derived from Swiss Federal Statistical Ofﬁce 2013 diagnosis-related case costs
for a sample population of 7614 mechanically ventilated adult ICU patients with a
SAPS II score >30 and an ICU stay 3 days.
c Based on the average cost of standard doses of piperacillin/tazobactam or
daptomycin reported by medical administration staff from two Swiss university
hospitals.
d Includes acquisition cost for 4 parenteral nutrition bags (139.6 CHF), physician
salary (7.34 CHF for 0.1 h), and nurse salary for 0.5 h/day for 4 days (100.6 CHF).
Medical staff costs based on 2013 average gross wages reported by the Swiss Federal
Statistics Ofﬁce and a prior time-and-motion study in Swiss university hospitals
[23].
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one infection was 19. The estimated incremental cost per infection
avoided was 63,048 CHF, indicating that the cost of the inter-
vention is more than offset by the cost savings associated with the
reduction in nosocomial infections.
The probabilistic sensitivity analysis conﬁrmed the robustness
of the main ﬁndings (Fig. 2a). Consistent with the original model,
the probabilistic analysis showed an estimated 5.2% absolute
reduction in nosocomial infections and an expected mean cost
reduction of 3296 CHF per patient with the SPN strategy. Model-
derived probabilities of observing reductions in infections and to-
tal hospital costs with SPN were 98.4% and 97.6%, respectively.
Results of the one-way deterministic sensitivity analysis are
depicted in the tornado diagram in Fig. 2b. A mean overall cost
reduction with SPN remained evident when each parameter value
varied within the extremes of the probability distribution, further
conﬁrming the robustness of the main ﬁndings. The magnitude of
reduction in the risk of nosocomial infection had the largest effect
on the estimated cost savings; however, even the lower limit of the
estimated reduction in nosocomial infections resulted in a net cost
savings with SPN.4. Discussion
The Swiss SPN study was the ﬁrst randomised controlled trial to
demonstrate that individually optimised energy supplementationTable 3
Medical costs and clinical outcomes based on the deterministic simulation model.
Clinical outcomes
EN SPN Diff
Infections/100 patients, n 38.0 32.7 5.
ICU LOS, d 13.4 12.9 0.
Ward LOS, d 21.0 20.3 0.
Mechanical ventilation, h 54.3 50.9 3.
Antimicrobial therapy, d 5.92 5.48 0.
Intervention e e e
Total e e e
Incremental cost effectiveness
Cost per infection avoided, CHF
Abbreviations: CHF, Swiss francs; EN, enteral nutrition; ICU, intensive care unit; LOS, leng
a Calculated using the formula (EN cost e SPN cost)/(infections with EN e infections
deﬁned as an incremental cost savings for each unit of beneﬁt due to the intervention.with SPN confers meaningful clinical beneﬁts to ICU patients who
fail to achieve targeted energy delivery with EN alone [16]. In the
present analysis, we used data from the SPN study to sequentially
characterise the relationships between SPN, cumulative energy
deﬁcit, nosocomial infection, and medical resource consumption. A
signiﬁcant cost reduction was found with SPN, suggesting that
optimisation of energy provision using SPN is a cost-effective
strategy in selected critically ill adults.
Comprehensive analysis of data from the SPN study yielded
several important observations. First, SPN signiﬁcantly improved
energy delivery and prevented further progression of energy deﬁ-
cits during the initial days following ICU admissionwithout causing
overfeeding. In the multivariable analysis of cumulative energy
deﬁcit during days 1e8, SPN administration was the strongest in-
dependent predictor of energy target attainment, resulting in a
mean improvement of 2320 kcal in cumulative energy balance.
Second, a negative cumulative energy balance was independently
associated with the risk of nosocomial infection. After adjustment
for model covariates, the risk of nosocomial infection was reduced
by 10% for each 1000 kcal decrease in cumulative energy deﬁcit.
While previous studies have evaluated the effect of both under-
feeding and overfeeding on clinical outcomes in critically ill pop-
ulations [7,25e27], this ﬁnding conﬁrms a direct quantitative
association between cumulative energy target and an objective
clinical outcome. Finally, linear regression analyses demonstrated a
statistically signiﬁcant association between nosocomial infection
and medical resource consumption, including antibiotic use,
duration of mechanical ventilation, and length of stay in the ICU
and hospital.
The pharmacoeconomic evaluation showed that the total costs
associated with SPN were exceeded by the savings accrued due to
the reduction in resource consumption, most of which was attrib-
utable to a reduction in infectious morbidity. Providing SPN to
patients who failed to achieve the targeted energy delivery by day 3
resulted in a savings of 3339 CHF per patient compared with EN
alone. Based on the estimated number of patients needed to
nourish to avoid one infection (n ¼ 19), SPN would be expected to
result in an incremental cost of 63,048 CHF for each infection
avoided. In contrast to the typical scenario in which providing
treatment to the number of patients required to prevent a single
clinical event imposes an additional cost, the negative incremental
cost observed in our analysis indicates that the cost of SPN is more
than offset by the savings associated with the corresponding
reduction in nosocomial infections. Notably, our ﬁndings therefore
show that supplemental administration of PN to critically ill pa-
tients for whom EN is insufﬁcient confers both ameaningful clinical
beneﬁt and a clear cost advantage.Cost (CHF)
erence EN SPN Difference
30 e e e
41 67,491 65,424 2067
63 39,825 38,627 1198
43 4637 4344 293
44 385 356 29
e 247 247
112,338 108,999 ¡3339
¡63048a
th of stay; SPN, supplemental parenteral nutrition.
with SPN); a negative incremental cost indicates pharmacoeconomic dominance,
Fig. 2. A. Scatterplot of 10,000 probabilistic sensitivity analysis runs. The results demonstrate a 98.4% probability of a reduction in nosocomial infection and a 97.6% probability of
reduced hospital costs with the use of SPN compared with EN alone. B. Tornado diagram depicting the results of the one-way deterministic sensitivity analysis. The x-axis represents
the difference in total hospital costs for SPN compared with EN; the y-axis lists the clinical and resource utilisation parameters in decreasing order of their effect on the difference in
total hospital cost. Values were varied by one parameter at a time within the extremes of the 95% CI. The 95% CI was taken directly from the multivariable regression analyses for
clinical and resource utilisation parameters; for cost estimates, the 95% CI was calculated assuming a SD equal to 20% of the mean value. Abbreviations: Ant, antibiotic; CI, conﬁdence
interval; EN, enteral nutrition; ICU, intensive care unit; Inf, infection; MV, mechanical ventilation; PSA, probabilistic sensitivity analysis; SD, standard deviation; SPN, supplemental
parenteral nutrition.
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receiving less than the targeted enteral feeding after two days
should be considered for supplementary PN [1]. To date, however,
no study has formally evaluated the cost-effectiveness of this
strategy in critically ill patients with an indication for artiﬁcial
nutrition. In a cost analysis based on data from a Belgian study
(EPaNIC) [28], Vanderheyden et al. [29] reported that early initia-
tion of SPN (day 2) following ICU admission resulted in higher
overall costs compared with late SPN (day 8). In contrast to the
study upon which our economic model was based, the EPaNIC trial
included a large proportion of patients without a ﬁrm indication for
PN and a shorter median stay in the ICU. Additionally, the early
hypertonic glucose load during the acute phase coupled with slight
overfeeding in the early PN group likely contributed to a higher
infection rate [30], thereby inﬂuencing overall cost. The economic
evaluation of the CALORIES trial, which found no difference in
clinical outcome between PN and EN, yielded inconclusive results
[31]. Conversely, the Swiss SPN study demonstrated that initiating
SPN on day 4 in critically ill patients for whom artiﬁcial nutrition is
indicated but EN is insufﬁcient and carefully adjusting energy de-
livery to avoid overfeeding reduces energy deﬁcits and decreases
metabolic complications [16]. Our ﬁndings further demonstratethat the lower energy deﬁcit is associated with a reduced risk of
infection, which results in decreased resource consumption and
lower overall cost. Consistent with this latter ﬁnding, Doig and
colleagues [32] reported signiﬁcant cost savings attributable to the
use of early PN in critically ill patients with short-term relative
contraindications to EN. We note, however, that the analysis
differed from the present study in two signiﬁcant respects. First, the
clinical trial upon which the economic analysis was based evalu-
ated a separate clinical indication for PN (contraindication to EN)
and showed no statistically signiﬁcant effect on clinical outcomes
[33]. Second, the pharmacoeconomic evaluation was based on a
cost-minimisation analysis, whichdunlike the cost-effectiveness
model used in our studydassumes equivalent clinical outcomes
for the interventions under consideration. Nonetheless, the cost
beneﬁt attributable to the use of early PN is generally consistent
with our results.
Certain limitations of our study should be considered. The cost-
effectiveness model was based on clinical outcomes in a trial
conducted in two Swiss university hospitals with a dedicated
nutrition support team and cost estimates derived from cost data
for the Swiss healthcare system. The extent to which the ﬁndings
are generalizable to hospitals with limited nutrition support
L. Pradelli et al. / Clinical Nutrition 37 (2018) 573e579578resources and different cost structures is unknown. The model-
based approach was selected because the original study protocol
did not include an economic analysis; therefore, not all relevant
cost and resource consumption parameters were measured. The
use of modelling techniques was considered the most appropriate
method to integrate clinical study outcomes with cost data from
separate sources to facilitate evaluation of economic outcomes.
Moreover, because the model-based analysis employs stochastic
techniques to balance the uncertainty of the effect size estimates
used in the model, the generalisability of the ﬁndings to other
clinical settings is improved [34]. Comparison of model pre-
dictions with observed data from the SPN trial suggest that the
model results represent conservative estimates, with more
modest reductions in nosocomial infections compared with esti-
mates based on observed data. The apparent underestimation of
the beneﬁts associated with SPN in our model might be explained
in part by the possibility that not all of the effect of SPN on
nosocomial infection is mediated through an improvement in
energy balance. Similarly, the effect of SPN on the length of stay
might be due not only to the reduction in nosocomial infections,
but also to an improvement in general clinical status. Finally,
while several PN products were used in the SPN study, the
acquisition cost for PN products in the cost-effectiveness analysis
was based on a single representative product. However, given the
marginal differences in cost between products used in the SPN
study, our analysis would be expected to yield similar results for
each product. It's important to note that these cost-savings apply
and are limited to a very sick ICU subpopulation of long-stayers
(median length of ICU stay ¼ 11 days), which constitute the
potentially chronic critically ill patients.
In conclusion, a pharmacoeconomic analysis based on Swiss
healthcare costs demonstrated that the savings accrued due to
reduced resource consumption, in particular length of hospital stay,
should more than offset the initial costs for SPN. Collectively, these
ﬁndings demonstrate that optimisation of energy provision using
SPN in selected ICU patients results in both a meaningful clinical
beneﬁt and a clear cost advantage.
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